1. [First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer].
- Author
-
Guan ZZ, Liu DG, Yu BM, Wu WQ, Shi D, Zhao Y, Wei YQ, Zou LQ, Wu XD, Zhuang W, Feng FY, Zhang P, Yu SY, Xiong HH, Fu Q, Zheng S, Huang JJ, Wu G, Yang CY, Sun SR, and Ruan QL
- Subjects
- Adult, Aged, Capecitabine, Colorectal Neoplasms mortality, Deoxycytidine adverse effects, Female, Fluorouracil analogs & derivatives, Humans, Male, Middle Aged, Survival Rate, Antimetabolites, Antineoplastic therapeutic use, Colorectal Neoplasms drug therapy, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use
- Abstract
Objective: To evaluate the efficacy and safety of capecitabine as first-line therapy in patients with advanced and recurrent colorectal cancer., Methods: From December 2000 to November 2001, sixty patients with advanced and recurrent colorectal cancer received first-line capecitabine treatment given at a dose of 1250 mg/m(2) twice daily, on days 1 - 14 every 21 days. At least 2 cycles were administered., Results: The overall response rate was 23.3% with 14 PR, 24 SD (40.0%) and 15 PD. The median survival time was 14.7 months. The survival rate was 63.9% at 12-months and 33.4% at 24-months. Grade III-IV adverse effects were diarrhea in 4 patients (6.6%), anemia in 2 (3.3%) and hand-foot syndrome (HFS) in 1 (1.7%); Grade I-II adverse effects were hyperpigmentation in 20 (33.3%), HFS in 18 (30.0%) and diarrhea in 10 (16.7%)., Conclusion: Capecitabine is an efficacious and better-tolerated alternative treatment for the patients with advanced and recurrent colorectal cancer.
- Published
- 2004